VIA
SLDB icon

Virtus Investment Advisers’s Solid Biosciences SLDB Stock Holding History

Virtus Investment Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458K Buy
+45,826
New +$347K 0.11% 222

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's SLDB Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in Solid Biosciences (SLDB) in Q2 2026: 45,826 shares worth $458K. The stake represents 0.11% of the portfolio and ranks #222 among its holdings.

157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Virtus Investment Advisers held 45,826 shares of Solid Biosciences worth $458K as of Q2 2026.
  • Solid Biosciences was a new Virtus Investment Advisers position in Q2 2026.
  • Solid Biosciences made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #222 holding.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.